Investment Thesis
Aprea Therapeutics is a pre-revenue biopharmaceutical company with a fortress balance sheet featuring $46.5M in cash against $4.0M in liabilities, providing 16+ years of runway at current $2.8M annual burn. However, the complete absence of revenue, negative operating income, and unproven clinical pipeline preclude a positive rating without visibility into development milestones and time to marketable product.
Strengths
- Exceptional liquidity position with 8.92x current ratio and minimal leverage (0.00x debt/equity)
- Strong cash reserves of $46.5M representing 98% of total assets, providing substantial development runway
- Modest and improving losses with diluted EPS improving 17.9% YoY despite continuing burn
Risks
- Complete absence of revenue with no clear near-term commercialization pathway evident from fundamentals
- Negative operating cash flow of -$2.8M indicates ongoing cash burn without offsetting revenue generation
- Business model entirely unproven with no marketed products; success dependent entirely on uncertain clinical trial outcomes
Key Metrics to Watch
- Operating cash flow trend and absolute burn rate per quarter
- Cash runway depletion timeline relative to anticipated clinical milestones
- Insider buying/selling sentiment and Form 4 filing frequency
Financial Metrics
Revenue
N/A
Net Income
-3.3M
EPS (Diluted)
$-0.22
Free Cash Flow
-2.8M
Total Assets
47.6M
Cash
46.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-7.9%
ROA
-6.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.92x
Quick Ratio
8.92x
Debt/Equity
0.00x
Debt/Assets
8.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:38:30.799609 |
Data as of: 2026-03-31 |
Powered by Claude AI